Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone
Zidavi is recommended by the Infectious Disease Society of America
Subscribe To Our Newsletter & Stay Updated
